187 related articles for article (PubMed ID: 21146749)
1. Safety and efficacy of patient specific intramuscular injection of HGF plasmid gene therapy on limb perfusion and wound healing in patients with ischemic lower extremity ulceration: results of the HGF-0205 trial.
Powell RJ; Goodney P; Mendelsohn FO; Moen EK; Annex BH;
J Vasc Surg; 2010 Dec; 52(6):1525-30. PubMed ID: 21146749
[TBL] [Abstract][Full Text] [Related]
2. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.
Powell RJ; Simons M; Mendelsohn FO; Daniel G; Henry TD; Koga M; Morishita R; Annex BH
Circulation; 2008 Jul; 118(1):58-65. PubMed ID: 18559703
[TBL] [Abstract][Full Text] [Related]
3. Clinical Safety and Preliminary Efficacy of Plasmid pUDK-HGF Expressing Human Hepatocyte Growth Factor (HGF) in Patients with Critical Limb Ischemia.
Cui S; Guo L; Li X; Gu Y; Fu J; Dong L; Song H; Chen X; Lu Y; Hu C; Xiao F; Zhu D; Wu Z; Zhang Q
Eur J Vasc Endovasc Surg; 2015 Oct; 50(4):494-501. PubMed ID: 26122834
[TBL] [Abstract][Full Text] [Related]
4. Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan.
Morishita R; Shimamura M; Takeya Y; Nakagami H; Chujo M; Ishihama T; Yamada E; Rakugi H
Curr Gene Ther; 2020; 20(1):25-35. PubMed ID: 32416690
[TBL] [Abstract][Full Text] [Related]
5. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of Hepatocyte Growth Factor in the Treatment of Critical Limb Ischemia.
Gu Y; Cui S; Wang Q; Liu C; Jin B; Guo W; Liu C; Chu T; Shu C; Zhang F; Han C; Liu Y
Mol Ther; 2019 Dec; 27(12):2158-2165. PubMed ID: 31805256
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia.
Shigematsu H; Yasuda K; Iwai T; Sasajima T; Ishimaru S; Ohashi Y; Yamaguchi T; Ogihara T; Morishita R
Gene Ther; 2010 Sep; 17(9):1152-61. PubMed ID: 20393508
[TBL] [Abstract][Full Text] [Related]
7. Treatment of Critical Limb Ischemia by pIRES/VEGF165/HGF Administration.
Barć P; Antkiewicz M; Śliwa B; Baczyńska D; Witkiewicz W; Skóra JP
Ann Vasc Surg; 2019 Oct; 60():346-354. PubMed ID: 31200059
[TBL] [Abstract][Full Text] [Related]
8. SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial.
Shishehbor MH; Rundback J; Bunte M; Hammad TA; Miller L; Patel PD; Sadanandan S; Fitzgerald M; Pastore J; Kashyap V; Henry TD
Vasc Med; 2019 Jun; 24(3):200-207. PubMed ID: 30786835
[TBL] [Abstract][Full Text] [Related]
9. Safety evaluation of clinical gene therapy using hepatocyte growth factor to treat peripheral arterial disease.
Morishita R; Aoki M; Hashiya N; Makino H; Yamasaki K; Azuma J; Sawa Y; Matsuda H; Kaneda Y; Ogihara T
Hypertension; 2004 Aug; 44(2):203-9. PubMed ID: 15238569
[TBL] [Abstract][Full Text] [Related]
10. Interim analysis results from the RESTORE-CLI, a randomized, double-blind multicenter phase II trial comparing expanded autologous bone marrow-derived tissue repair cells and placebo in patients with critical limb ischemia.
Powell RJ; Comerota AJ; Berceli SA; Guzman R; Henry TD; Tzeng E; Velazquez O; Marston WA; Bartel RL; Longcore A; Stern T; Watling S
J Vasc Surg; 2011 Oct; 54(4):1032-41. PubMed ID: 21684715
[TBL] [Abstract][Full Text] [Related]
11. pUDK-HGF Gene Therapy to Relieve CLI Rest Pain and Ulcer: A Phase II, Double-Blind, Randomized Placebo-Controlled Trial.
Gu Y; Cui S; Liu C; Zhao J; Li M; Li Y; Yang X; Lv B; Li M; Zhao W; Guo W; Huang J; Huang W; Qiu Z; Zhao J; Yin P; Qin T; Zhu D; Sun W; Ren K; Lu Y; Cheng X; Du L; Xiao F; Zhang Q; Wu Z
Hum Gene Ther; 2021 Aug; 32(15-16):839-849. PubMed ID: 33726499
[TBL] [Abstract][Full Text] [Related]
12. Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients With Peripheral Artery Disease (STOP-PAD) Trial: Six-Month Results.
Hammad TA; Rundback J; Bunte M; Miller L; Patel PD; Sadanandan S; Fitzgerald M; Pastore J; Kashyap V; Henry TD; Shishehbor MH
J Endovasc Ther; 2020 Aug; 27(4):669-675. PubMed ID: 32419594
[No Abstract] [Full Text] [Related]
13. Safety of a non-viral plasmid-encoding dual isoforms of hepatocyte growth factor in critical limb ischemia patients: a phase I study.
Henry TD; Hirsch AT; Goldman J; Wang YL; Lips DL; McMillan WD; Duval S; Biggs TA; Keo HH
Gene Ther; 2011 Aug; 18(8):788-94. PubMed ID: 21430785
[TBL] [Abstract][Full Text] [Related]
14. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia.
Gupta PK; Chullikana A; Parakh R; Desai S; Das A; Gottipamula S; Krishnamurthy S; Anthony N; Pherwani A; Majumdar AS
J Transl Med; 2013 Jun; 11():143. PubMed ID: 23758736
[TBL] [Abstract][Full Text] [Related]
15. A phase I clinical study of naked DNA expressing two isoforms of hepatocyte growth factor to treat patients with critical limb ischemia.
Gu Y; Zhang J; Guo L; Cui S; Li X; Ding D; Kim JM; Ho SH; Hahn W; Kim S
J Gene Med; 2011 Nov; 13(11):602-10. PubMed ID: 22015632
[TBL] [Abstract][Full Text] [Related]
16. Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients.
Abdul Wahid SF; Ismail NA; Wan Jamaludin WF; Muhamad NA; Abdul Hamid MKA; Harunarashid H; Lai NM
Cochrane Database Syst Rev; 2018 Aug; 8(8):CD010747. PubMed ID: 30155883
[TBL] [Abstract][Full Text] [Related]
17. Early results and lessons learned from a multicenter, randomized, double-blind trial of bone marrow aspirate concentrate in critical limb ischemia.
Iafrati MD; Hallett JW; Geils G; Pearl G; Lumsden A; Peden E; Bandyk D; Vijayaraghava KS; Radhakrishnan R; Ascher E; Hingorani A; Roddy S
J Vasc Surg; 2011 Dec; 54(6):1650-8. PubMed ID: 22019148
[TBL] [Abstract][Full Text] [Related]
18. The Scottish-Finnish-Swedish PARTNER study of taprostene versus placebo treatment in patients with critical limb ischemia.
Belch JJ; Ray S; Rajput-Ray M; Engeset J; Fagrell B; Lepäntalo M; McKay A; Mackay IR; Ostergren J; Ruckley CV; Salenius J
Int Angiol; 2011 Apr; 30(2):150-5. PubMed ID: 21427652
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of plasmid DNA expressing two isoforms of hepatocyte growth factor in patients with critical limb ischemia.
Kibbe MR; Hirsch AT; Mendelsohn FO; Davies MG; Pham H; Saucedo J; Marston W; Pyun WB; Min SK; Peterson BG; Comerota A; Choi D; Ballard J; Bartow RA; Losordo DW; Sherman W; Driver V; Perin EC
Gene Ther; 2016 Mar; 23(3):306-12. PubMed ID: 26649448
[TBL] [Abstract][Full Text] [Related]
20. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial.
Comerota AJ; Throm RC; Miller KA; Henry T; Chronos N; Laird J; Sequeira R; Kent CK; Bacchetta M; Goldman C; Salenius JP; Schmieder FA; Pilsudski R
J Vasc Surg; 2002 May; 35(5):930-6. PubMed ID: 12021709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
